The insulin pump market is projected to reach $14bn in the same period, as per GlobalData analysis. Insulet also secured label expansion for Omnipod 5 device from the FDA allowing for its use in ...

Insulet first launched its Omnipod 5 patch-pump for people with Type 1 diabetes in 2022. Now, the device is also indicated for people with Type 2 diabetes ages 18 years and older.

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced its groundbreaking Omnipod ...

OAKVILLE, ON, April 7, 2025 /CNW/ - Insulet Corporation (PODD), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced that Omnipod 5 is now ...

Insulet delivered third-quarter revenue growth of 25% in constant currency and pushed up gross margin by 150 basis points after a savvy decision to consolidate all pumps to the Omnipod 5 platform ...

Additionally, Insulet shared that it has two planned clinical trials for new algorithms for its platforms. One involves ...

ACTON, Mass., August 26, 2024--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today ...

Insulet Corporation, a global leader in tubeless insulin pump technology with its Omnipod brand of products, announced that Omnipod 5 is now commercially available in Canada. Omnipod 5 is the first ...

Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced its groundbreaking Omnipod 5 Automated Insulin Delivery System is ...

ACTON, Mass., August 26, 2024--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced ...